news

Sanofi and UCB partner for breakthrough innovation in immune-mediated diseases

Posted: 11 March 2014 | | No comments yet

Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules…

Sanofi

Sanofi (EURONEXT : SAN and NYSE : SNY) and UCB announce today they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat a wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.

“Immune-mediated diseases affect individuals, families, and communities and impact the economies of countries and nations, making this poorly understood category of diseases a significant public health burden.” said Dr. Elias Zerhouni, President, Global R&D at Sanofi. “Joining efforts with UCB, we will address a scientific challenge in immunology, and increase the chances of accelerating the discovery and development of future therapies.”

“We partner Sanofi’s significant expertise, strong capabilities and resources with UCB’s cuttingedge research skills and breakthrough innovations. Together we can maximize the opportunity to treat diseases currently treated by biologic agents with small molecules and thus benefit millions of people suffering from severe diseases,” commented Ismail Kola, President UCB NewMedicines.

UCB NewMedicines, the research arm of UCB, has used an innovative approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly efficacious in patients. A dedicated team of scientists will be formed under the leadership of Sanofi and UCB, and will join forces in a discovery and development based collaboration to characterize and identify new potential therapies.

Under the terms of the agreement, Sanofi and UCB will share costs and profits on a 50/50 basis. UCB will be entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi, potentially exceeding € 100 million.

Related organisations

,

Related people